PATENT CLAIM ANALYSIS

Application Number: 15741609
Application Type: Utility
Filing Date: 2018-01
Publication Date: 2018-07
Patent Classification: ["514", "256000"]

Abstract:
This invention provides compounds that are inhibitors of HDAC2. The compounds (e.g., compounds according to Formula (I) or any one of Compounds 100-175) accordingly are useful for treating, alleviating, or preventing a condition in a subject such as a neurological disorder, memory or cognitive function disorder or impairment, extinction learning disorder, fungal disease or infection, inflammatory disease, hematological disease, or neoplastic disease, or for improving memory or treating, alleviating, or preventing memory loss or impairment.

Claim (Index 18):
The method of  claim 16 , wherein the method is a combination therapy for treating, alleviating, and/or preventing post-traumatic stress disorder or Alzheimer's disease and the pharmaceutically active ingredient administered is selected from Aricept\u00ae (donepezil), memantine, galantamine and Excelon\u00ae (rivastigmine).

Metadata:
- Claim Count in Document: 10.0
- Percentile: 86.0
- Lexical Diversity: 1.78846
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['15321410', '16063682', '15067605', '15559375', '15769414']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7712257026864968
- 35 USC 102 Novelty (BERT): 0.5312405826977009
- Combined Prediction Score: 0.7472271906876172
- Mean Citation Score: 308.301164
- Max Citation Score: 331.46362
- Similarity Product: 240.92266374556425

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test